Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2018-05-22 Regulatory Filings
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
ATL1103 Phase II trial results published in leading journal 2 pages 33.7KB
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 23 May 2018 about the publication of Phase II clinical trial results for ATL1103 in the European Journal of Endocrinology. It discusses the acceptance and expected benefits of the publication, provides background on the drug and disease, and includes contact information. There are no financial statements, regulatory filings, or detailed financial data. The document is an announcement of a scientific publication and clinical trial results, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is also not a presentation, call transcript, or management report. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2018-05-22 English
Response to ASX Price & Volume Query 5 pages 171.6KB
Regulatory Filings Classification · 100% confidence The document is a letter from ASX Compliance to Antisense Therapeutics Limited regarding a query about unusual trading activity in the company's securities. The letter requests information about any undisclosed material information that could explain the trading volume and price changes, and the company's response confirms compliance with listing rules and provides explanations related to recent capital raising and investor interest. The content is a regulatory inquiry and response about market disclosure and trading compliance, not a financial report, earnings release, or presentation. It is a regulatory filing related to continuous disclosure obligations under ASX Listing Rules, specifically Listing Rule 3.1. The document does not contain financial statements, management discussion, or other report content but is a compliance communication with the exchange.
2018-05-13 English
Becoming a substantial holder 3 pages 145.1KB
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for images and no substantive textual content. The total character count is very low (503 characters), and there is no indication of any report content, financial data, or announcements. Given the lack of textual information and the presence of only images, this document does not fit any specific detailed report category. It is best classified as a Regulatory Filing (RNS), which serves as a fallback category for miscellaneous filings that do not fit other categories.
2018-05-08 English
Appendix 3B - Completion of Allotment 12 pages 727.1KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) announcement used for notifying the market about new issues of securities, applications for quotation of additional securities, and related agreements. It details the class and number of securities issued, issue price, purpose of the issue, and other related information. This type of document is specifically related to capital raising and changes in the company's capital structure. It is not a financial report, earnings release, or management discussion, but rather a formal announcement of a share issue and quotation application. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2018-05-08 English
Change of Director's Interest Notice - (RM, MD, GP, WG, GM) 10 pages 416.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y' and is described as a 'Change of Director's Interest Notice' under ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including number of shares/options held before and after the change, dates of changes, and nature of the transactions. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades or director dealings. It is not an annual report, earnings release, or any other financial report. It is specifically a Director's Dealing report as per the filing definitions.
2018-05-08 English
Appendix 3B 12 pages 717.5KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the number and class of securities issued, issue price, purpose of the issue, shareholder approvals, and calculation of placement capacity under ASX rules. It references specific ASX rules (7.1, 7.1A) and includes sections on quotation of securities and agreements related to the listing of these securities on the ASX. The content is regulatory in nature, focused on the announcement of a new share issue and related compliance disclosures. It does not contain financial statements, earnings data, management discussion, or other report types. This matches the definition of a Share Issue/Capital Change announcement, which covers new share issues and capital structure changes.
2018-05-06 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.